title: Surface epithelial tumours of the ovary.
abstract: Surface epithelial tumours (SET) constituted 65.7% of all the ovarian tumours. Benign tumours were 182 (71.9%), of low malignant potential (LMP) 11 (4.4%) and frank malignant 60 (23.7%). Maximum number of cases, 102 (40.3%) belonged to 3rd decade. Mean age for serous cystoma was 31.5% years as compared to 30.8 years for mucinous cystoma. The commonest presenting feature was the abdominal lump observed in 182 cases (71.9%) and pain in abdomen in 120 (47.4%). Serous cystomas were t he most frequent tumours and comprised of 32.21% of all the ovarian tumours or 46.01% of all the SET or 65.56% of all the cystic SET. Seventeen (11.7%) of serous tumours were bilateral. Mucinous cystomas constituted 14.55% of all the ovarian tumours or 30.8% of all the SET. These tumours were bulky (78.6%; 15 cm diameter) and multilocular (83.9%). Mucinous cystadenocarcinoma was the commonest malignant epithelial tum our (36.6%). Endometroid carcinoma comprised 3.65% of all the SET or 8.4% of all the ovarian malignancy. Squamous metaplasia was seen in one case whereas 2 cases were of mesodermal mixed tumour with heterologous element as rhabdomyosarcoma. Clear cell carcinoma, Brenner tumour and unclassified group constituted 0.79%, 1.18% and 1.58% of all SET respectively.
authors.affiliation: Department of Pathology, Jawaharlal Nehru Medical College, Aligarh Muslim University.
authors.forename: V
authors.initials: V
authors.lastname: Maheshwari
authors.forename: S P
authors.initials: SP
authors.lastname: Tyagi
authors.forename: K
authors.initials: K
authors.lastname: Saxena
authors.forename: N
authors.initials: N
authors.lastname: Tyagi
authors.forename: R
authors.initials: R
authors.lastname: Sharma
authors.forename: M
authors.initials: M
authors.lastname: Aziz
authors.forename: F
authors.initials: F
authors.lastname: Hameed
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000473:pathology; D000236:Adenoma / Q000473:pathology; D001948:Brenner Tumor / Q000473:pathology; D002277:Carcinoma / Q000473:pathology*; D018284:Cystadenocarcinoma, Serous / Q000473:pathology; D018291:Cystadenoma, Mucinous / Q000473:pathology; D018293:Cystadenoma, Serous / Q000473:pathology; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000473:pathology*; D012189:Retrospective Studies